Target Name: NLRP11
NCBI ID: G204801
Review Report on NLRP11 Target / Biomarker Content of Review Report on NLRP11 Target / Biomarker
NLRP11
Other Name(s): NLR family pyrin domain containing 11 | nucleotide-binding oligomerization domain protein 17 | PYPAF6 | NACHT, LRR and PYD containing protein 11 | NOD17 | Nucleotide-binding oligomerization domain protein 17 | NACHT, LRR and PYD domains-containing protein 11 | Nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 11 | PYPAF7 | PAAD- and NACHT-containing protein 10B | NACHT, leucine rich repeat and PYD containing 11 | NAL11_HUMAN | PAN10 | NLR family pyrin domain containing 11, transcript variant 1 | NACHT, LRR and PYD domains-containing protein 11 (isoform 1) | PYRIN-containing APAF1-like protein 6 | FLJ26273 | CLR19.6 | NLRP11 variant 1 | NALP11 | nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 11 | PAAD-and NACHT domain-containing protein 10 | PAAD- and NACHT-containing protein 10

NLRP11: Regulation of Stress Proteins and Cell Adhesion InNLRP11-related Diseases

The NLRP11 protein is a member of the NLR family of proteins that contain a pyrin domain. NLRP11 is a 22 kDa protein that is expressed in many different tissues, including brain, muscle, and heart. The primary function of NLRP11 is to regulate the formation of stress-proteins, which are involved in the stress response. NLRP11 is also involved in the regulation of cell adhesion, and has been shown to play a role in the development of cancer.

One of the key features of NLRP11 is its pyrin domain, which is a protein-coding region that is characterized by a specific sequence of amino acids. The pyrin domain is involved in the formation of the protein structure and is thought to play a structural role in the regulation of NLRP11 function.

NLRP11 has been shown to be involved in a number of different cellular processes, including the regulation of stress protein formation, cell adhesion, and the development of cancer. For example, studies have shown that NLRP11 is involved in the regulation of the formation of stress-proteins, which are involved in the stress response. These stress-proteins are thought to play a key role in the regulation of cellular processes such as cell division, apoptosis, and inflammation.

In addition to its role in stress protein regulation, NLRP11 has also been shown to be involved in the regulation of cell adhesion. cell adhesion is the process by which cells stick together to form tissues and organs. NLRP11 has been shown to play a role in the regulation of cell adhesion by regulating the formation of tight junctions, which are a type of cell-cell adhesion structure.

NLRP11 has also been shown to be involved in the development of cancer. Studies have shown that NLRP11 is often expressed in a variety of cancer types and that it is involved in the regulation of cellular processes that are commonly associated with cancer development. For example, research has shown that NLRP11 is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle and is often disrupted in cancer cells.

In conclusion, NLRP11 is a protein that is involved in a number of different cellular processes, including stress protein regulation, cell adhesion, and cancer development. Its pyrin domain, which is characterized by a specific sequence of amino acids, is thought to play a key role in these processes. As a result, NLRP11 is a potential drug target or biomarker for a variety of diseases.

Protein Name: NLR Family Pyrin Domain Containing 11

Functions: Involved in inflammation

The "NLRP11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NLRP11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

NLRP12 | NLRP13 | NLRP14 | NLRP2 | NLRP2B | NLRP3 | NLRP3 Inflammasome | NLRP3P1 | NLRP4 | NLRP5 | NLRP6 | NLRP7 | NLRP8 | NLRP9 | NLRP9P1 | NLRX1 | NMB | NMBR | NMD3 | NMDA receptor | NME1 | NME1-NME2 | NME2 | NME2P1 | NME3 | NME4 | NME5 | NME6 | NME7 | NME8 | NME9 | NMI | NMNAT1 | NMNAT2 | NMNAT3 | NMRAL1 | NMRAL2P | NMRK1 | NMRK2 | NMS | NMT1 | NMT2 | NMTRQ-TTG10-1 | NMTRQ-TTG12-1 | NMTRV-TAC1-1 | NMU | NMUR1 | NMUR2 | NNAT | NNMT | NNT | NNT-AS1 | NOA1 | NOB1 | NOBOX | NOC2L | NOC2LP2 | NOC3L | NOC4L | NOCT | NOD1 | NOD2 | NODAL | NOG | NOL10 | NOL11 | NOL12 | NOL3 | NOL4 | NOL4L | NOL4L-DT | NOL6 | NOL7 | NOL8 | NOL9 | NOLC1 | NOM1 | NOMO1 | NOMO2 | NOMO3 | Non-protein coding RNA 185 | NONO | NOP10 | NOP14 | NOP14-AS1 | NOP16 | NOP2 | NOP53 | NOP56 | Nop56p-associated pre-rRNA complex | NOP58 | NOP9 | NOPCHAP1 | NORAD | NOS1 | NOS1AP | NOS2 | NOS2P1 | NOS2P2 | NOS2P3